Enveric Biosciences, Inc.
ENVB
$1.21
-$0.08-6.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.46% | -54.17% | -52.69% | -33.04% | -23.35% |
| Depreciation & Amortization | -1.89% | -1.76% | -1.42% | -0.64% | 4.91% |
| Other Operating Expenses | -129.57% | -- | -- | -- | -- |
| Total Operating Expenses | -41.44% | -53.13% | -51.56% | -29.77% | -17.60% |
| Operating Income | 41.44% | 53.13% | 51.56% | 29.77% | 17.60% |
| Income Before Tax | 44.59% | 59.06% | 55.38% | 25.21% | 13.50% |
| Income Tax Expenses | -69.20% | 101.62% | 102.06% | 102.06% | 101.94% |
| Earnings from Continuing Operations | 44.63% | 56.26% | 52.26% | 19.08% | 6.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.63% | 56.26% | 52.26% | 19.08% | 6.39% |
| EBIT | 41.44% | 53.13% | 51.56% | 29.77% | 17.60% |
| EBITDA | 42.28% | 54.09% | 52.40% | 30.28% | 17.97% |
| EPS Basic | 82.57% | 76.04% | 66.71% | 39.72% | 40.67% |
| Normalized Basic EPS | 82.39% | 67.02% | 54.03% | 15.31% | 24.49% |
| EPS Diluted | 82.57% | 76.04% | 66.71% | 39.72% | 40.67% |
| Normalized Diluted EPS | 82.39% | 67.02% | 54.03% | 15.31% | 24.49% |
| Average Basic Shares Outstanding | 249.19% | 167.64% | 99.05% | 50.73% | 49.57% |
| Average Diluted Shares Outstanding | 249.19% | 167.64% | 99.05% | 50.73% | 49.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |